Overview

Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

Status:
Recruiting
Trial end date:
2024-04-29
Target enrollment:
Participant gender:
Summary
This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 (mirdametinib) combination in participants with tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
BeiGene
Collaborators:
SpringWorks Therapeutics
SpringWorks Therapeutics, Inc.